AR094761A1 - PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME - Google Patents

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME

Info

Publication number
AR094761A1
AR094761A1 ARP140100439A ARP140100439A AR094761A1 AR 094761 A1 AR094761 A1 AR 094761A1 AR P140100439 A ARP140100439 A AR P140100439A AR P140100439 A ARP140100439 A AR P140100439A AR 094761 A1 AR094761 A1 AR 094761A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
oral administration
fexofenadine
prepare
composition
Prior art date
Application number
ARP140100439A
Other languages
Spanish (es)
Inventor
Daste Georges
Derouet Benjamin
Renouard Marie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR094761A1 publication Critical patent/AR094761A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para administración oral, que comprende: 1 - 3,5 %p de pectina de alto contenido en metoxi, 40 - 68 %p de glicerol, 16 - 29 %p de agua, 0 - 1 %p de al menos un tensioactivo, 3 - 5 %p de fexofenadina o una sal de la misma farmacéuticamente aceptable, 12 - 24 %p de un excipiente farmacéutico capaz de complejarse con la fexofenadina o su sal farmacéuticamente aceptable, 0 - 5 %p de al menos otros ingrediente seleccionado del grupo que consiste en: sustitutos del azúcar, agentes saborizantes y/o agentes colorantes, siendo los porcentajes en peso relativos al peso total de la composición, y estando el pH de la composición dentro del intervalo de 2,8 a 3,2. Reivindicación 5: La composición farmacéutica de una cualquiera de las reivindicaciones 1 a 4, en donde el excipiente farmacéutico es b-ciclodextrina. Reivindicación 6: La composición farmacéutica de una cualquiera de las reivindicaciones 1 a 5, que es masticable.Claim 1: A pharmaceutical composition for oral administration, comprising: 1 - 3.5% p of high methoxy content pectin, 40-68% p of glycerol, 16-29% p of water, 0 - 1% p of at least one surfactant, 3-5% p of fexofenadine or a pharmaceutically acceptable salt thereof, 12-24% p of a pharmaceutical excipient capable of complexing with the fexofenadine or its pharmaceutically acceptable salt, 0-5% p of at least other ingredients selected from the group consisting of: sugar substitutes, flavoring agents and / or coloring agents, the percentages by weight being relative to the total weight of the composition, and the pH of the composition being in the range of 2.8 to 3 ,2. Claim 5: The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical excipient is b-cyclodextrin. Claim 6: The pharmaceutical composition of any one of claims 1 to 5, which is chewable.

ARP140100439A 2013-02-14 2014-02-12 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME AR094761A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305173 2013-02-14

Publications (1)

Publication Number Publication Date
AR094761A1 true AR094761A1 (en) 2015-08-26

Family

ID=47739181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100439A AR094761A1 (en) 2013-02-14 2014-02-12 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME

Country Status (4)

Country Link
AR (1) AR094761A1 (en)
TW (1) TW201440808A (en)
UY (1) UY35329A (en)
WO (1) WO2014125052A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740193A4 (en) * 2018-01-15 2022-03-02 Seattle Gummy Company Semi-solid anti-histamine compositions and methods of making and using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (en) 1995-02-28 2003-07-10 Aventis Pharma Inc MEDICINAL PREPARATIONS FOR PIPERIDINAL CANOL DERIVATIVES
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
WO2007017905A1 (en) * 2005-08-05 2007-02-15 Lupin Limited Oral pharmaceutical suspension compositions of fexofenadine
KR101303479B1 (en) * 2011-07-28 2013-09-06 (주)씨엘팜 Composition for edible film and pharmaceutical preparation for edible film containing drugs

Also Published As

Publication number Publication date
WO2014125052A1 (en) 2014-08-21
TW201440808A (en) 2014-11-01
UY35329A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
BR112014009087A2 (en) xylitol stabilized etanercept formulations
CU20140068A7 (en) SUBSTITUTED TRIAZOLOPIRIDINS
ECSP13013050A (en) FORMULATION FOR ANTIBODY ANTI- 4 7
BR112015000229A2 (en) stable aqueous formulations of etanercept
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
BR112014014341A2 (en) METHYL INTERMEDIATE, ITS PREPARATION METHOD AND USES, AND PHARMACEUTICAL COMPOSITION
BR112014011162A2 (en) purine derivatives for the treatment of viral infections
AR089004A1 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS, METHOD, USE
BR112015004984A2 (en) stable aqueous formulations of adalimumab
BRPI0922804B8 (en) pharmaceutical composition in a solid dosage form comprising bendamustine and a pharmaceutically acceptable excipient
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
CU20120171A7 (en) SUBSTITUTED TRIAZOLOPIRIDINS
RS53598B1 (en) Topical compositions for preserving or restoring the integrity of mucosae
BR112017026287A2 (en) hydroxypropyl beta-cyclodextrin compositions and methods
AR094374A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
BR112015017251A2 (en) pharmaceutical compositions comprising nitroxil donors
BR112013028776A2 (en) kit and use of a pharmaceutical or nutraceutical composition
CO6231001A2 (en) STABILIZATION OF VITAMIN B12
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
UY35848A (en) TIENOPIRIMIDINS
BR112013004455A2 (en) compositions for gastric delivery of active agents
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
CO6491061A2 (en) FORMULATION OF STABLE OMEPRAZOL PHARMACEUTICAL FOR ORAL ADMINISTRATION
BR112015005347A2 (en) compound, pharmaceutical composition, and method for treatment or prophylaxis of HIV infection or for treatment, prophylaxis, or delay in the onset of AIDS
AR090975A1 (en) N-ETIL-4-HYDROXYL-1-METHYL-5- (METHYL (2,3,4,5,6-PENTAHYDROXIHEXIL) AMINO) -2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE

Legal Events

Date Code Title Description
FB Suspension of granting procedure